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1. Introduction:
Orally disintegrating tablets (ODTs) rapidly disintegrate in the mouth without
chewing upon oral administration and without the need for water, unlike other
drug delivery systems and conventional oral solid immediate-release dosage forms.
ODT dosage form; also commonly known as fast melt, quick melts,  fast
disintegrating and orodispersible systems have the unique property of
disintegrating the tablet in the mouth in seconds.1 For acute conditions, this dosage
form is easier for patients to take anytime, anywhere those symptoms occur. For
chronic conditions, it is assumed to improve compliance. Some important advantages
of ODT drug delivery over others are ease of swallowing for patients and
convenience of taking the medication  anytime  without  the  need  of  water.  Some
limitations  include  difficulty  in developing  extremely high doses (typically in
excess of 500mg) and sometimes-extensive taste masking of bitter tasting actives.2
Orally  disintegrating  dosage  forms  are  often  formulated  for  existing  drugs  with  an
intention to extend the  patent life of the drug through product differentiation.
They are evaluated against the innovator drug in a bioequivalence study in humans
to establish comparability of pharmacokinetic parameters. Drug delivery systems are
technologies that transport the active drug into the body’s circulatory system. Drug
can be  delivered into the body by various means, depending on its physical and
chemical properties. Some may  alter the method of taking the drug; others alter the
desired therapeutic activity.3
The advent of new drug delivery systems can clearly differentiate a drug product in
today’s highly  competitive pharmaceutical market. To better understand the
concept of the drug delivery system, one needs to know how a drug delivery
system can be a valuable and cost effective  life  cycle  management   resource.4
Pharmaceutical  companies  worldwide  have recognized  various  drug  delivery
systems  as  powerful  marketing  tools  to  differentiate products,  extend  product
life  cycles,  and  even  improve  the  efficacy  of  a  drug.  Several example include
Claritin ODTs, Actiq (transmucosal dosage form for patient  compliance), and
Cardiazem XL (osmotic dosage form for extended release).5,  6 The drug delivery
market encompasses a wide array of technologies that cover various routes of
administration such as oral, nasal, transdermal and inhalation.
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The oral route remains most popular owing to the ease of administration,
manufacturing and regulatory strategy. The increasing popularity of orally
disintegrating dosage forms is in part owing to various factors such as patient
preference and life cycle management. Some reasons for patient preference include
fast  disintegration, good mouth-feel, easy to handle, easy to swallow, and effective
taste masking (for tablet based technologies).8 A perceived benefit for ODT is the
ease of administration to elderly and pediatric  populations and other patient
populations that have difficulty swallowing traditional tablets or capsules.
A customer study was done to measure consumer/patient reactions to fast dissolving
tablets. The population size was 5000 and spanned across a diverse age group.
Patients were given a conventional tablet and an ODT and asked various questions.
A significant majority of the patients said they ‘‘would or might’’ prefer a fast
dissolve dosage form over a regular tablet or liquid. Only 12% of the patients
rejected fast dissolve tablets.  Most of the patients also indicated that they would
ask their doctor for a fast dissolve version and would purchase a fast dissolve if
available.9
Life cycle management allows for differentiation of product in the market.
According to data monitor,   drugs   worth   $37   billion   will   lose   patent
protection   between   2000   and 2010.Development  of  an  ODT  formulation
within  the  patent  expiration  period  can  add significant patent life to the
formulation as it cannot be substituted at the pharmacy counter until an equivalent
ODT is available in the market.10
1.1. Manufacturing methods:
The  processes  described  hereunder  are  utilized  to  develop  ODTs,  depending
on  its capabilities and limitations, in addition to developing the product within an
acceptable period of time satisfying all the specific needs of the product. Each
technology utilizes one or more combinations of processes described below to
develop ODT drug delivery systems. ODT development consists of three parts1
1. Evaluating the need to taste mask the drug.
2. Incorporating the taste masked/non-taste masked drug into the tablet matrix.
3. Packaging.
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Taste masking:
Taste masking of drug may be achieved with preventing the exposure of drug to the
tongue through processing or adding competing taste-masking agents. Exposure of
solubilized drug to the oral cavity can be  prevented by encapsulation in polymer
systems or complexation. The approaches are as follows.12
• Layering the drug onto inert beads using a binder followed by coating with
a taste- masking polymer.
• Granulating the drug and coating with a taste masking polymer.
• Spray drying the drug dispersed or dissolved in a polymeric solution to
get taste- masked particles.
• Complexation by the use of inclusion in cyclodextrins.
• Psychological modulation of bitterness.
Layer/coat process:
The layering process involves deposition of successive layers of an active compound
onto the granules of the inert starter seeds such as sugar spheres or microcrystalline
cellulose beads. Sugar spheres (Non Pareil) or  microcrystalline spheres (Celpheres)
can be used as initial substrate in the preparation of beads by the layering process.
In the layering process, the bitter drug is dissolved or dispersed in an aqueous or non-
aqueous solvent, depending on its solubility characteristics and ease of processing.
Binder is added to the solution to form liquid bridges between the primary particles.13
The various polymers used for taste-masking purpose are Eudragits, ethylcellulose,
hydroxyl propyl methyl cellulose, hydroxyl propyl cellulose, polyvinyl alcohol and
polyvinyl acetate. The polymer is dissolved in an aqueous or non-aqueous solvent
depending on its solubility characteristic and anti-tack agents such as talc,
magnesium stearate are added to improve processing and prevent agglomeration.14
Sometimes  taste  masking  is  possible  by  combining  layer/coat  in  a  single
process,  i.e., incorporating the drug in solution/suspension form containing a
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polymer that serves both as a binder and as a taste-masking agent and then depositing
the drug onto beads.12
Granulation:
Taste masking by granulation is achieved by decreasing the surface area of the
drug by increasing its  particle size. The additional benefit obtained is ease of
processing  for  tablet  compression  as  the  majority  of  drugs  have  a  low  bulk
density. Additionally, polymers that serve as binders and taste-masking agents may
be incorporated, which reduce the perception of taste. Granulation may be achieved
with or without the use of a solvent. Dry granulation involves the use of forming
compacts/slugs that are milled for blending. Wet granulation can be achieved by
using the fluid bed process or high-shear granulation. In the fluid bed process, the
drug  is  suspended  in  the  bed  with  air,  and  a  binder  is  sprayed  from  the  top.  The
granules formed  are  porous  and  not  amenable  to  further  processing  like
coating.  In  high-shear granulation, the granule formation occurs by spraying a
liquid binder onto drug/mixture of drugs with excipients that are being agitated by
combined action of an impeller and chopper. The granules obtained are dense and
may be used directly or coated further in a fluid bed. This approach is suitable for
high-dose drugs (>50mg) with unpleasant taste.14
Spray drying:
For taste-masking application, the drug is either dissolved or dispersed along with
bulking agent (polymer)  and occasionally, a binding agent is also added if
required, in a suitable solvent. Spray drying consists of  four stages: atomization
of feed into a spray, spray–air contact (mixing and flow), drying of spray
(moisture/volatiles evaporation) and separation of dried product from the air. The
solvent used for spray drying process may be aqueous or non- aqueous.  Product
obtained  upon  spray  drying  yields  high  porosity  granules  or  beads containing
encapsulated drug.14,15
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Complexation:
Taste masking by inclusion complexation is possible by physically entrapping the
drug in cone shaped structures known as cyclodextrins. Cyclodextrins are bucket
shaped oligosaccharides produced from starch. Owing to their peculiar structure and
shape, they possess  the  ability  to  entrap  guest  molecules  in  their  internal
cavity.  Drug  inclusion complexes can be formed by a variety of techniques that
depend on the property of the drug, the equilibrium kinetics, other formulation
ingredients, processes, and the final dosage form desired.
In  all   these   processes,   a   small   amount   of   water   is   required   to   achieve
thermodynamic equilibrium.14 The initial equilibrium to form the complex is very
rapid; the final equilibrium takes a longer time. The drug,  once inside the
cyclodextrin cavity, makes conformational changes so as to attach itself to the
complex and to take maximum advantage of the weak Vander Waals forces.
Complexation is also possible through the use of ion-exchange resins. Both
anionic and cationic  types   are   available.  The  preparation  of  the  taste-masked
complex  involves suspending the resin in a solvent in which the drug is dissolved.
For liquid preparations, the drug–resin complex can be used as it is. For  solid
dosage forms, the complex may be processed by filtration or direct drying. Drug
loading up to 50% is possible with this process. Some commercially available ion-
exchange resins that may be used for taste  masking are based on methacrylic acid
and divinylbenzene and styrene divinyl benzene polymer.14,16
1.2. Orodispersible tablets:
Regardless of different advancements in drug delivery, the oral route remains the
perfect route for the administration of therapeutic agents because the low cost of
therapy and ease of administration lead to high levels of patient compliance.1
Recently fast dissolving drug delivery systems have started gaining popularity for
the reason of speedy  disintegration or dissolution, self administration even without
water or chewing. This  can  be  achieved  by   various  conventional  methods  like
direct   compression,  wet granulation,    molding,   spray   drying,   freeze   drying
and    sublimation.    Some    patented  technologies  are  also  there  to  formulate  this
dosage form such as Zydis technology, WOWtab technology,  Orasolv  technology,
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Durasolv  technology,  Flashdose  technology,   Flashtab technology, Oraquick
technology, Quick-Dis technology and Nanocrystal technology. For masking the
obnoxious taste of the drug different polymers are brought into play for coating,
different resins utilized  for  complex formation, sweeteners and flavors draw on in
direct compression while formulating this form of delivery system.15
More than 50% of pharmaceutical products are orally administered for several
reasons. This route of administration is considered as the most widely used route
as it offers advantages like ease of administration, versatility, patient compliance
and accurate dosing. Undesirable taste  is  one of the  important  formulation
problems  that  are  encountered  with  such  oral products. Difficulty in swallowing is
also a common problem of all age groups, especially the elderly and pediatrics,
because of physiological changes associated with these groups. 17
Faster onset of action may be very valuable for faster relief. A liquid dosage form,
like a solution or dispersion will be suitable for faster action; masking the taste of a
bitter drug and improving the rate of dissolution of less soluble drug become
important considerations in liquid  formulations.18Also,  it  is  well  known  that
liquid  dosage  forms,  suffer  from  the drawbacks of inaccuracy of dosage and
inconvenience of transportation and handling. Hence considering  all  the  above
points  the  solid  dosage  form,  which  can  be  administered  or swallowed as a
liquid,  where  in  the  bitter  taste  of  drug  is  masked,  would  be  a  very  ideal  dosage
form. One such approach is fast mouth dissolving tablet.19,20
Fast dissolving drug delivery systems have started gaining popularity and acceptance
as new drug  delivery  systems  which  aim  to  enhance  safety  and  efficacy  of
drug  molecule  by formulating  a  convenient  dosage  form  for  administration  and
to  achieve  better  patient compliance.  Their growing importance was underlined
recently when European Pharmacopoeia adopted the term “Oro-dispersible tablet”
as a tablet that to be placed in the mouth where it disappears rapidly before
swallowing.21
Mouth dissolving drug delivery system emerged from the desire to provide the
patient with more  conventional means of taking their medication. It is difficult
for many patients to swallow tablets and  gelatin capsules. Hence they do not
comply with prescription, which results in non-compliance and  ineffective therapy.
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In some cases such as motion sickness, sudden episodes of allergic attacks or
coughing  and unavailability of water, swallowing conventional tablets may be
difficult. Pediatric and geriatric patients experience particularly this difficulty. Such
problems can be resolved by means of mouth dissolving tablet.22
When put on tongue, this tablet disintegrates instantaneously, releasing the drug,
which  dissolves  or  disperses  in  the  saliva.  Some  drugs  are  absorbed  from  the
mouth, pharynx and esophagus as the saliva passes down into the stomach. In such
cases, bioavailability of drug is significantly greater than those observed from
conventional tablet dosage form.
Desired criteria:
Mouth dissolving tablet should23
• Not require water to swallow, but it should dissolve or disintegrate in the
mouth in matter of seconds.
• Be compatible with taste masking.
• Be portable without fragility concern.
• Have a pleasing mouth feel.
• Leave minimal or no residue in the mouth after oral administration.
• Exhibit low sensitivity to environmental conditions as humidity and
temperature. The several advantages of fast dissolving dosage forms are
• Ease of administration for patients, those who are not co-operative.
• Quick disintegration and dissolution of the dosage form.
• Can be swallowed without water.
• Allows high drug loading.
• Can be designed to leave minimal or no residue in the mouth after
administration and also provide a pleasant mouth feel.23
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1.3. Technologies used for preparing ODTs:
Various techniques used for preparing mouth dissolving tablets are freeze drying,
molding, sublimation, spray drying, mass-extrusion and direct compression.
Patented technologies for mouth dissolving tablets are  Zydis technology, Durasolv
technology, Orasolv technology, Flash  dose  technology,  WOW  technology,  Flash
tab  technology,  Ora-quick  technology, Quick-Dis Technology and Nano-crystal
Technology.
Freeze drying:
A process, in which water is sublimated from the product after freezing, is called
freeze drying. Freeze-dried forms offer more rapid dissolution than other available
solid products. The lyophilization  process  imparts glossy amorphous structure to
the bulking agent and sometimes to the drug, thereby enhancing the dissolution
characteristics of the formulation.
The influence of various formulation and process parameters on the characteristics of
rapidly disintegrating  tablets in freeze dried form is investigated by scientists who
concluded that maltodextrins are useful in the formulation of fast dissolving tablets
made by freeze drying.24
Molding:
Tablets produced by molding are solid dispersions. Physical form of the drug in
the tablets depends whether and to what extent; it dissolves in the molten carrier.
The drug can exist as discrete particles or microparticles dispersed in the matrix.
It can dissolve totally in the molten carrier to form solid solution or dissolve
partially in the molten carrier  and  the remaining particles stay undissolved and
dispersed in the matrix. Disintegration  time,  drug  dissolution  rate  and  mouth
feel  will  depend  on  the  type  of dispersion or dissolution.
No-vacuum lyophilization is another process which involves the evaporation of a
solvent from a drug solution or suspension at standard pressure.24
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Sublimation:
Compressed tablets composed of highly water-soluble excipients as tablet matrix
material often do not dissolve rapidly in the water. Porous tablets exhibit good
mechanical strength and  dissolve  quickly.  Inert  solid  ingredients  (e.g.  urea,
ammonium  carbonate,  camphor, naphthalene) are added to other tablet  excipients
and the blend is compressed into tablet.
Removal of volatile material by sublimation generated a porous structure.24
Spray drying:
Highly porous and fine powders can be produced by spray drying process, as the
processing solvent is evaporated rapidly during spray drying. For fast dissolving
tablets, they developed formulation by using mannitol as bulking agent, hydrolyzed
and non-hydrolyzed gelatin as support matrix, sodium starch glycolate as
disintegrant and acidic material (e.g. citric acid) and/or alkali material (e.g. sodium
bicarbonate) to  enhance disintegration and dissolution. When immersed in an
aqueous medium, the tablets compressed from  spray-dried powder, disintegrated
within 20 secs.27
Mass extrusion:
This technology  involves  softening the  active  blend  using the  solvent  mixture
of water soluble polyethylene glycol (PEG) using methanol and expulsion of
softened mass through the extruder or syringe to get a cylinder of the product into
even segments using heated blade to form tablets. The dried cylinder can also be used
to coat granules of bitter tasting drugs and thereby masking their bitter taste.
Direct compression:
It is the easiest way to manufacture tablets. Conventional equipment, commonly
available excipients and a  limited number of processing steps are involved in
direct compression. Directly compressed tablets disintegration and solubilization
depends on single or combined action of disintegrants, water soluble excipients and
effervescent agent. Disintegrant efficacy is strongly affected by tablet size and
hardness. Large  and hard tablets have disintegration time more than that usually
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required. As consequences, products with optimal disintegration properties often
have  medium  to  small  size  and  /or  high  friability  and  low  hardness.  Breakage  of
tablet edges during handling, tablet rupture during the opening of blister alveolus
all results from insufficient physical resistance.27
Disintegrants  have  major  role  in  the  disintegration  and  dissolution  process  of
mouth dissolving Tablets made by direct compression. To ensure a high
disintegration rate, choice of  suitable  type  and  an  optimal  amount  of  disintegrant  is
important.
Other formulation components such as water-soluble excipients or effervescent
agents can further  enhance   dissolution  or  disintegration  properties.  But  main
drawback  of  using effervescent excipients is their highly hygroscopic nature. 1
The understanding of disintegrant properties and their effect on formulation has
advanced during last few years, particularly regarding so called super-
disintegrants. Disintegration efficiency is based on force equivalent concept,
which is the combined measurement of swelling force development and amount of
water absorption. Force equivalent expresses the capability of disintegrant to
transform absorbed water into swelling force. The optimization of tablet
disintegration was defined by means of disintegrant critical  concentration. Below
this  concentration, the tablet disintegration  time  is  inversely  proportional  to
disintegrant concentration and above that disintegration time remains
approximately constant or even increases. 3
Patented technologies: Zydis technology:
Zydis, the best known of the fast-dissolving/disintegrating tablet preparations, was
the first marketed new  technology tablet. The tablet dissolves in the mouth
within seconds after placement on the tongue. A Zydis tablet is produced by
lyophilizing or freeze-drying the drug in a matrix usually consisting of gelatin. The
product is very lightweight and fragile, and must be dispensed in a special blister
pack. Patients should be advised not to push the tablets through the foil film, but
instead peel the film back to release the tablet. The Zydis product is made to dissolve
on the tongue in 2 to 3 secs.28
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The Zydis formulation is also self-preserving because the final water concentration
in the freeze-dried product is too low to allow for microbial growth. A major
claim of the Zydis product is increased bioavailability compared to traditional
tablets. Because of its dispersion and dissolution in saliva while still in the oral
cavity, there can be a substantial amount of pregastric absorption from this
formulation. Buccal,  pharyngeal and gastric regions are all areas of absorption of
the Zydis formulation. Any pre-gastric  absorption avoids first-pass metabolism
and  can  be  an  advantage  in  drugs  that   undergo  a  great   deal  of  hepatic
metabolism.  However,  if  the  amount  of  swallowed  drug  varies,  there  is  the
potential for inconsistent bioavailability.28
While the claimed increase in bioavailability is debatable, it is clear that the major
advantage of the Zydis  formulation is convenience. The amount of drug that
could be incorporated should generally be less than 60mg for soluble drugs. The
particle size of the insoluble drugs should  be  less  than  50mm  and  not  more  than
200mm  to  prevent  sedimentation  during processing. There are some
disadvantages to the Zydis  technology. The process of freeze- drying  is  a
relatively   expensive   manufacturing   process.   The   Zydis   formulation   is   very
lightweight and fragile, and therefore should not be stored in backpacks or the
bottom  of purses.  Finally,  the  Zydis  formulation  has  poor  stability  at  higher
temperatures  and humidities.28
Orasolv technology:
Orasolv was Cima’s first fast-dissolving/disintegrating dosage form. The Orasolv
technology, unlike Zydis, disperses in the saliva with the aid of almost
imperceptible effervescence. The OraSolv technology is best described as a fast
disintegrating tablet; the tablet matrix dissolves in less than one minute, leaving
coated drug powder. The taste masking associated with the OraSolv formulation is
two-fold. The unpleasant flavor of a drug is not merely counteracted by sweeteners
or flavors; both coating the drug powder and effervescence are means of taste
masking  in  Orasolv.  This  technology  is  frequently  used  to  develop  over-the-
counter formulations.29
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The major disadvantage of the Orasolv formulations is its mechanical strength. The
Orasolv tablet has the appearance of a traditional compressed tablet. However, the
Orasolv tablets are only  lightly  compressed,  yielding  a  weaker  and  more  brittle
tablet  in  comparison  with conventional tablets. For that reason, Cima  developed
a special handling and packaging system for OraSolv. An advantage that goes
along with the  low  degree of compaction of OraSolv is that the particle coating
used for taste masking is not compromised  by fracture during processing.
Lyophilization and high degrees of compression, as utilized in Orasolv’s primary
competitors, may disrupt such as taste masking approach. The Orasolv technology is
utilized in six  marketed products. These formulations can accommodate single or
multiple active ingredients and tablets containing more that 1.0gr of drug have been
developed.
Their  disintegration  time  is  less  than  30secs.  The  Orasolv  formulations  are
not  very hygroscopic.30
Durasolv technology:
Durasolv  is  Cima’s  second  generation  fast-dissolving/disintegrating  tablet
formulation. Produced in a fashion similar to Orasolv, Durasolv has much higher
mechanical strength than its predecessor due to the use  of higher compaction
pressures during tableting. Durasolv tablets  are  prepared  by  using  conventional
tabletting  equipment  and  have  good  rigidity (friability less than that 2%). The
Durasolv product is thus  produced in a faster and more cost-effective manner.
Durasolv is so durable that it can be packaged in either in traditional blister
packaging, pouches or vials.30
One disadvantage of Durasolv is that the technology is not compatible with larger
doses of active   ingredients,  because  the  formulation  is  subjected  to  such
high  pressures  on compaction.  Unlike   Orasolv,  the  structural  integrity  of
any  taste  masking  may  be compromised with high drug doses.  The  drug
powder coating in Durasolv may become fractured  during  compaction,  exposing
the  bitter-tasting  drug  to  a  patient’s  taste  buds. Therefore, the Durasolv
technology is best suited for formulations including relatively small doses of active
compound.30
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Flash dose technology:
Fuisz Technologies has three oral drug delivery systems that are related to fast
dissolution. The first two generations of quick-dissolving tablets, Soft Chew and EZ
chew, require some chewing. The Flashdose technology utilizes a unique spinning
mechanism to produce a floss- like crystalline structure, much like cotton candy.
This crystalline sugar can then incorporate the active drug and be compressed into a
tablet. The final product has a very high surface area for dissolution. It disperses and
dissolves quickly once placed onto the tongue.30
WOWtab technology:
The WOWtab  fast-dissolving/disintegrating  tablet  formulation  has  been  on  the
Japanese market   for   a   number   of   years.   WOWtab   technology   is   patented
by   Yamanouchi Pharmaceutical Corporation. The WOW in WOWtab signifies the
tablet is to be given “With Out Water”.
It has just recently been introduced into the U.S. The WOWtab technology utilizes
sugar and sugar-like (e.g., mannitol) excipients. This process uses a combination of
low mouldability saccharides (rapid dissolution)  and  high mouldability saccharide
(good binding property). The two different types of saccharides are  combined to
obtain a tablet formulation with adequate hardness and fast dissolution rate. Due
to its  significant hardness, the WOWtab formulation is a bit more stable to the
environment than the Zydis or Orasolv. It is suitable for both conventional bottle and
blister packaging.
The taste masking technology utilized in the WOWtab is proprietary, but claims
to offer superior mouth feel due to the patented Smooth melt action. The WOWtab
product dissolves quickly in 15secs or less.30
Flashtab technology:
Prographarm laboratories have patented the Flashtab technology. This technology
involves the preparation of rapidly disintegrating tablet which consists of an active
ingredient in the form  of  microcrystals.  Drug  microgranules  may  be  prepared  by
using  the  conventional techniques  like  coacervation,  extrusion-spheronization,
simple  pan  coating  methods  and microencapsulation. The microcrystals of
microgranules of the active ingredient are added to the granulated mixture of
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excipients prepared by wet or dry granulation and compressed into tablets. All the
processing utilized the conventional tabletting technology,  and the tablets
produced are reported to have good mechanical strength and disintegration time less
than one minute.28
Oraquick technology:
The  Oraquick  fast-dissolving/disintegrating  tablet  formulation  utilizes  a
patented  taste masking  technology.  KV  Pharmaceutical  claims  its  microsphere
technology,  known  as MicroMask,  has  superior  mouth  feel  over  taste-masking
alternatives.  The  taste  masking process does not utilize solvents of any kind, and
therefore leads to faster and more efficient production.  Also,  lower  heat  of
production  than  alternative  fast-dissolving/disintegrating technologies makes
Oraquick appropriate for heat-sensitive drugs. KV  Pharmaceutical also claims that
the matrix that surrounds and protects the drug powder in  microencapsulated
particles  is  more  pliable,  meaning  tablets  can  be  compressed  to  achieve
significant mechanical strength without disrupting taste masking.
Oraquick claims quick dissolution in a matter of seconds, with good taste-masking.
There are no products using the OraQuick technology currently on the market, but
KV Pharmaceutical has  products  in   development   such  as  analgesics,  scheduled
drugs,  cough  and  cold, psychotropics and anti-infectives.30
Nanocrystal technology:
For ODTs, Élan’s proprietary NanoCrystal technology can enable formulation and
improve compound  activity and final product characteristics. Decreasing particle
size increases the surface  area,  which  leads  to  an  increase  in  dissolution  rate.
This  can  be  accomplished predictably and efficiently using NanoCrystal
technology.
NanoCrystal particles are small particles of drug substance, typically less than
1000 nm in diameter, which are produced by milling the drug substance using a
proprietary wet milling technique.
NanoCrystal colloidal dispersions of drug substance are combined with water-
soluble GRAS (Generally  regarded as safe) ingredients, filled into blisters, and
lyophilized. The resultant wafers are remarkably robust, yet dissolve in very small
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quantities of water in seconds. This approach is especially attractive when working
with highly potent or hazardous materials because it avoids manufacturing
operations (e.g., granulation,  blending and tabletting) that generate large quantities
of aerosolized powder and present much higher risk of  exposure. The freeze-drying
approach also enables small quantities of drug to be converted into ODT dosage
forms because manufacturing losses are negligible.30
1.4. Evaluation of Orodispersible tablets: Weight variation:
Tablets are designed to contain a specific amount of drug in a specific amount of
tablet formula; the weight of the tablet being made is routinely measured to help
ensure that a tablet contains the proper amount of drug.
Average weight of 20 tablets is calculated using an electronic balance. Individual
weight of each tablet is  calculated and compared with the average weight. The
tablets meet USP specifications if no more than 2 tablets outside the percentage
limit and if no tablet differs by more than 2 times the percentage limit.31
Hardness:
Tablet hardness has been defined as “the force required to break a tablet in a
diametric compression  test”.  To perform this test, the tablet is placed between
two anvils, force is applied to the anvils, and the crushing strength that just causes
the tablet to break is recorded.
Hardness  is  thus  sometimes  called  as  “tablet  crushing  strength”.  Several
devices  that commonly serve the purpose of determining the tablet hardness are the
Monsanto tester, the Strong-Cobb tester, the Pfizer tester and the Erweka tester.
Friability:
Tablet hardness  is  not  an  absolute  indicator  of  strength since  some
formulations,  when compressed into  very hard tablets, tend to “cap” on attrition
losing their crown portions. Therefore another measure of tablets strength, its
friability is often measured.
The laboratory friability tester is known as the Roche Friabilator. This device
subjects a number  of  tablets  to  the  combined  effects  of  abrasion  and  shock  by
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utilizing  a  plastic chamber that revolves at 25rpm, dropping the tablets from a
distance of 6 inches with each revolution.
Normally  a  preweighed  tablets  sample  is  placed  and  rotated  at  25rpm  for  4mins  or
100rpm for 1 min using a Roche Friabilator.  The tablets were then reweighed after
dusting and the percentage of weight loss was  calculated. The percentage weight
loss usually should not exceed 0.5-1%. When capping is observed on  friability
testing, the tablet should not be considered for commercial use, regardless of the
percentage of loss observed.32
Wetting time and water absorption ratio:
The wetting time of the tablets was measured using a simple procedure. Five
circular tissue papers of 10-cm diameter were placed in a petridish with a 10-cm
diameter. Ten milliliters of water containing a water-soluble  dye was added to the
petridish. A tablet was carefully placed on the surface of tissue paper in the
petridish at room temperature. The time required for water to reach the upper
surface of the tablets and completely wet them was noted as the wetting time.
To check for reproducibility, the measurements were carried out (n=6) and the
mean value was calculated.27
The weight of the tablet before keeping in the petridish was noted (Wb). The
wetted  tablet  from   the   petridish   was   taken   and   reweighed   (Wa). The  Water
absorption  ratio,  R,  was determined according to the following equation:
R = 100 *(Wa - Wb) / Wb
Where Wb and Wa are the weight before and after water absorption respectively.
Assay:
Weigh and finely powder not less than 20 tablets. Transfer an accurately weighed
portion of the powder,  equivalent to about one dose of the drug into a suitable
container. Add some amount of diluting fluid in which the drug gets completely
dissolved or gets extracted, stir by mechanical means until the drug gets into the
solution, the solution is made up to the volume by diluting fluid and mixed well.
The container is kept aside  for some time until all the suspended  particles  get
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settled.  The  clear  supernatant  is  separated  and  filtered  through membrane or
cellulose acetate filter.
The drug solution obtained is diluted if necessary with the diluting fluid and
checked for its absorbance  using spectrophotometer. The concentration of the drug
is  obtained  from the  standard  graph  and  the  average  amount  of  drug  in  the  tablets
was estimated.27
Disintegration time:
ODTs should be strong enough to survive rough handling during manufacturing and
shipping processes and yet friable enough to instantly dissolve or disintegrate into
small particles for easy swallowing by the patient. Conventional disintegration tests
for ordinary tablets may not allow  precise  measurement  of  the   disintegration
time  of  FDTs  because  of  their  fast disintegration. It is also hard to distinguish
among ODTs, which release their ingredients very quickly. In vitro testing may not
always reflect the real in vivo disintegration of tablets.
In general, the method described in the US Pharmacopoeia can produce data for
evaluation of the disintegration time; however, no additional information might be
extracted.
It  is  also  possible  to  evaluate  the  tendency  of  the  disintegration  kinetics  by
visual examination.  However, these evaluations are not sufficiently objective.
When developing FDT  formulations,  it  is  important  to  evaluate  the  effect  of
different  excipients  on  the disintegration time. In order to predict the
disintegration time of ODTs and the effects of different formulation parameters, a
few methods have been proposed.33
It is important to define a suitable method to better distinguish between the
disintegration times of different ODTs and to find better correlation between in
vitro and in vivo data. To achieve this goal, a modified dissolution apparatus was
applied to ODTs with disintegration times  too  fast  to  distinguish  the  differences
between  the  tablets  when  the  conventional methods were used.
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Texture analyzer method:
The Texture Analyzer was applied to the beginning and ending time of
disintegration. A tablet was adhered to the bottom of a probe, which was attached to
the load cell  with a very thin layer of glue or double-sided tape.  A small  amount of
water, usually 0.4ml, in a beaker or petridish was used as a disintegration medium at
room temperature.
The tablet was submerged in water and compressed against the bottom of the beaker
or Petri dish with a constant pressure.
The beaker side could be varied and the beaker could even be a water bath to
keep the temperature constant. The instrument was programmed to apply a moderate
force for up to 60 seconds so that the  penetration  distance could be measured as
the tablet was compressed while submerged in the water. The  probe distance
would be steady as the tablet remained cohesive. However, has the tablet
disintegrated the compression distances increased, because the probe had to keep
the pressure constant. The time for the  tablet to disintegrate was determined by
measuring the distance the probe traveled into the tablet. Topical time distance
profiles generated by the texture analyzer software enabled the calculation of
beginning and ending of disintegration time.32
Sieve method:
A simple device based on a shaking water bath is designed to measure the
disintegration time of ODTs. The device is composed of a sieve (no.10) and a glass
cylinder. The sieve is placed into the cylinder at a certain position so that 2ml of
disintegration medium fills the space below the sieve of the cylinder.
Then 1ml of the medium is added into the device, so that it is available for an
ODT to be tested. The  device is in a reciprocal shaking water bath kept at a
constant temperature of 37ºC. While the shaker is running in horizontal back-and-
forth motions with 150 rpm, an ODT is placed onto the top of the sieve immersed
in the disintegration medium. The ODT starts disintegration into small particles
and/or dissolves, and the time at which particles of the tablet go through the sieve
completely is  determined as the disintegration time. The disintegration time is
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measured using a stopwatch and this quick method gives reproducible data that are
highly useful in screening various formulations and testing many formulations
variables.27
Dissolution:
The development of dissolution methods for ODTs is comparable to the approach
taken for conventional tablets, and is practically identical. Dissolution conditions for
drugs listed in a pharmacopoeia monograph; in  a  good place to start with scouting
runs for a bioequivalent ODT.
USP Dissolution apparatus I and II can be used. USP I Basket apparatus may have
certain applications  but  sometimes  tablet  fragments  or  disintegrated  tablet
masses  may  become trapped on the inside top of the  basket at the spindle where
little or no effective stirring occurs, yielding irreproducible dissolution profiles .
The USP II Paddle apparatus, which is the most suitable and common choice for
orally disintegrating tablets, with a paddle speed of 50 rpm is commonly used.
Typically the dissolution of ODT is very fast when using USP monograph
conditions; hence slower paddle speeds may be utilized to obtain a profile. 33
The USP II  Paddle apparatus 50-100 rpm is suitable for dissolution testing of taste-
masked  drug  as  well.   The   media  used  for  the  taste-masked  drug  should  match  that
of the finished product to maximize the value  of  the test. HPLC is often required
to analyze dissolution aliquots due to presence of UV absorbing  components,
specifically flavors and sweetener. Excipient to drug ratio may be higher since the
formulation is designed to have good taste and mouth feel, decreasing the detection
of the drug to background  (excipient)  in the UV spectrophotometer.36
1.5. Advantages and limitations of ODTs:
The administration of ODTs may not inherently result in faster therapeutic onset,
but can circumvent problems such as difficulty in swallowing traditional solid oral
dosage forms such as tablets and capsules, particularly by pediatric and geriatric
patients.
The driving force in developing an ODT or other quick dissolving intraoral dosage
forms may include one or more of the following advantages.28
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Patient  compliance: To  allow  patients  to  easily  swallow  the  dosage  form
anytime, anywhere, for systemic absorption via rapid dissolution or disintegration in
the oral cavity.
Patient convenience: To enhance convenience to the patients in carrying and
administering these dosage forms especially when traveling by designing them to
taken without water.
Rapid absorption and onset of action:
To produce rapid absorption and faster onset of therapeutic efficacy mainly from
the rapid disintegrating/ dissolvingdosage forms, presumably due to rapid
disintegration, dissolution, and absorption.(i.e. antianginal therapy)33
Avoidance of first-pass effect:
To improve bioavailability owing to partial avoidance of first-pass metabolism
resulting from at least partial absorption through the buccal mucosa.
Elimination of water /improved stability:  To  provide  an  alternative  to  liquid
dosage forms (i.e., syrups,  solutions, dispersions) and thereby improve
physical/chemical stability of the drug.
In contrast to the advantages, many ODTs have limitations in terms or the amount
of drug that can be incorporated in each unit dose. For lyophilized dosage forms, the
drug dose must generally be less than 400 mg for insoluble drugs and less than 60
mg for soluble drugs. Also due to the nature of ODTs, special packaging is needed
for products that are fragile, which may add to the cost.32
1.6. Packaging of ODTs:
Packing is one of the important aspects in manufacturing ODT. The products
obtained by various technologies vary in some of the parameters especially in
mechanical strength to a good extent.
The products  obtained  by  lyophilization  process  including  various  technologies
such  as Zydis, Lyoc, Quicksolv and Nanocrystal are porous in nature, have less
physical resistance, sensitive to moisture and may degrade at higher humidity
conditions.
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For the above reasons products obtained require special packing. Zydis units are
generally packed  with  peelable  backing  foil.  Upon  prototype  selection,  selection
of  a  packaging configuration is a crucial part  of an ODT dosage form. Unlike
conventional tablets, where packaging provides a means  of  administration/transport,
ODTs  may  require  specialized packaging configurations owing to their relative
high moisture sensitivity and fragility.
In fact, the cost of packaging can be significant for commercialization one approach
used to overcome the  moisture and physical issues with ODTs is to select a rigid,
multilayer foil- based barrier material to protect the dosage form, with the blister
actually forming during the tablet formulation process.
In many cases, ODT are very fragile and regular push through blister packaging
may break the tablet upon  removing from the blister, so the packaging requires a
peelable closure. Packaging made from formable and flexible material can offer
protection from water, oxygen or ultraviolet rays as well as providing some physical
protection.36
The most common packaging configuration includes blister packaging and bottle
packaging. Blister packaged ODTs require specialized packaging equipment. In case
of CIMA’s PakSolv technology, tablets are picked and placed in individual blister
pockets ‘‘one at a time’’ using a robotic hand. In the case of freeze drying
technology, each blister needs to be filled individually with the solution or
suspension before subjecting it to freeze drying.
The final packaged dosage form has to be evaluated to verify packaging integrity.
One way to perform this  is  by  immersing  blisters  in  water  and  subjecting  them
to  a  vacuum for  a specified period of time. The blisters are then opened manually
and checked for presence of water droplets. Additionally, blisters and bottles should
be monitored in simulated shipping tests according to American Society for Testing
Materials (ASTM) standards.
An additional issue with blister packaging is the evaluation of child resistance. The
Consumer product safety  commission regulates this. The blisters are evaluated for
‘‘F ’’ value and appropriate designs need to be in place for child resistance and
senior friendliness.
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The F requirement is determined from the toxicity of the drug. In the case of
tablets, this would be the number of tablets that when ingested may produce a
serious injury or serious illness based on a 25-pound child. A package passes a
certain F rating, if 90% of the children from an initial 50-child test are not successful
in accessing the required F number of tablets.
Commercialization of ODTs has to go through the final evaluation of long-term
stability of the tablet   matrix and packaging   components as per  International
Conference on Harmonization (ICH) guidelines. As the majority of ODT dosage
forms  on  the  market  are  sensitive   to   moisture,   evaluation   of   moisture   vapor
transmission  rate  is  an  important parameter for assessing the shelf life of the
product. Some ODTs are sensitive to moisture to such an extent that, even during
processing or formulation development stages, temperature and humidity have to be
controlled to avoid long-term stability issues and may require special packaging.
Long-term stability studies done with several ODT products have indicated that the
foil–foil blister Paksolv blister design leads to a mere 0.1% increase in moisture
level compared to start  over six months at  40ºC /75% RH. The increase in moisture
level for high density polyethylene (HDPE) bottles is about 0.5% under the same
stability conditions at the end of six months based on CIMA in-house experience on
all bottled products.
Some of the products obtained from Durasolv, WOW tab, Pharmaburst, Oraquick,
Ziplets, etc. technologies  have sufficient mechanical strength to withstand
transport and handling shock so they are generally packed in push through blisters or
in bottles.
1.7.Ideal characteristics of ODTs: Fast disintegration:
ODTs should disintegrate in the mouth without additional water, the disintegration
fluid is provided by the saliva of the patient. The disintegrated tablet should
become a soft paste of liquid suspension, which can provide good mouth feel and
smooth swallowing.
The “fast disintegration” usually means disintegration of tablets in less than 1 min,
but it is preferred to have disintegration as soon as possible.5
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Taste:
As most drugs are unpalatable, ODTs usually contain the medicament in taste
masked form. Delivery  systems  dissolve  or  disintegrate  in  patient’s  mouth,  thus
releasing  the  active ingredients which come in contact with the taste buds and
hence, taste masking of the drugs becomes critical to patient compliance.
Drug properties:
For the ideal ODT technology, the drug properties should not significantly affect
the tablet property.  Many  drug  properties  could  potentially  affect  the
performance  of  ODTs.  For example, the solubility, crystal  morphology, particle
size, hygroscopicity, compressibility, and bulk density of a drug can significantly
affect  the final tablets characteristics, such as tablet  strength  and  disintegration.
The  ODT  technology  should  be  versatile  enough  to accommodate unique
properties of each drug.1
Tablet strength:
Because ODTs  are  designed  to  have  a  quick  dissolution/disintegration  time,
the  tablet porosity is  usually maximized to ensure fast water absorption into the
tablets. The key properties  of  the  tablets  are  fast  absorption  or  wetting  of
water  into  the  tablets  and disintegration of associated particles into  individual
components for fast dissolution. This requires that excipients should have high
wettability and the tablet structure should also have a highly porous network.
Moisture sensitivity:
ODTs should have low sensitivity to humidity. This problem can be especially
challenging because  many  highly  water-soluble  excipients  are  used  in
formulation   to   enhance   fast  dissolving   properties   as   well   as   to   create   good
mouth  feel.  Those  highly  water-soluble excipients are susceptible to moisture;
some will even deliquesce at high humidity. A good package  design  or  other
strategy  should  be  created  to   protect   ODTs  from  various environmental
conditions.49
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Friability:
In  order  to  allow oral  disintegrating  tablets  to  dissolve  in  the  mouth,  they  are  made
of either very porous or soft moulded matrices or compressed into tablets with very
low compression force, which makes the tablets  friable and/or brittle which are
difficult to handle, often requiring specialized peel-off blister packaging. To
overcome this problem, some companies introduced more robust forms of fast
dissolving tablets.50
Mouth feel:
Mouth feel is critical, and patients should receive a product that feels pleasant.
Any large particles from the  disintegrating tablet that are insoluble or slowly
soluble in saliva would lead to an unpleasant gritty feeling.  This can be overcome
by keeping the majority of the particles  below  the  detectable  size  limit.  In  some
cases,  certain  flavors  can  imbibe  an improved mouth feel perception, resulting in
a product that is perceived as being less gritty, even if the only change is the
flavor. Effervescence can be added to aid disintegration and improve mouth feel by
reducing the ‘dryness’ of a product.
1.8. Taste masking:
Success of ODT lies in its good taste. It does not matter if an ODT product
disintegrates in just a few seconds if it does not taste good. Disintegration time
variations of 5 to 30secs were considered to be fast by patients, and products in this
range were acceptable if the product tasted good. If the product tasted bad, it
didn’t matter what the disintegration time was. So product does not tastes good,
patients and physicians will  find another ODT as so many pharmaceutical
manufacturers are now switching to ODT technology and  offering a wider choice
of pharmaceutical actives covering many therapeutic categories to both physicians
and Patients.
Moreover, consumers  have  become  more  knowledgeable  and  demanding  due
to  many reasons including direct-to-consumer advertising, websites offering
medical information and the increasing number of  medicines available over the
counter. Nowadays, consumers also have a greater power of choice than ever before.8
Chapter I                                                                                                      Introduction	
	
Dept. of Pharmaceutics, AVPC, Chennai	 	25	
Taste is a sensation which is realized when a substance such as food, beverages or
drug  is  placed  in  to  the   oral  cavity.  This  sensation  is  the  result  of  signal
transudation from the receptor organs for taste, commonly known as taste buds.
These taste buds contain very sensitive nerve endings, which produce and transmit
electrical impulses via the seventh, ninth and tenth cranial nerves to those areas of
the brain, which are devoted to the perception of taste. More than 50 percent of
pharmaceutical products are orally administered  for  several  reasons;  undesirable
taste  is  one  of  the  important  formulation problems that are encountered with
certain drugs.9
Administration of bitter drugs orally with acceptable level of palatability is a key
issue for health care providers, especially with pediatrics and geriatric patients.
Thus, elimination or reduction of bitterness is an important main stay of product
evaluation in oral pharmaceutical formulation. Proven methods for bitterness
reduction have resulted in improved palatability of oral pharmaceutical
formulations. Various techniques  have been developed to improve taste like
polymeric coating strategies, complexation with cyclodextrins, ion exchange resins,
and salt formation using liposomes, microencapsulation technique and use of
excipients like flavors, sweeteners and surfactants. 9
Table I: Flavors used in ODTs: 12
Basic Taste Recommended Flavor
Sweet Vanilla, Bubblegum, Grape fruit
Salt Butter scotch, maple, apricot, peach, vanilla,
Sour Lemon, lime, orange, cherry, grapefruit
Bitter Liquorices, coffee, chocolate, mint, grapefruit,
cherry, peach, raspberry, orange, lemon, lime
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Selection of drug:
An ODT may have varying degrees of pre-gastric absorption and thus, the
pharmacokinetic profile  (including  the  maximum  plasma  concentration,  time  to
achieve  maximal  plasma concentration, and area  under the plasma concentration
time curve of an equal dose of an ODT  and  a  conventional  oral  dosage  form)
will  vary.  Therefore,  the  ODT  will  not  be bioequivalent to the conventional oral
dosage form.51
The ideal characteristics of a drug for dissolution in the mouth and pre-gastric
absorption from an ODT include:
• No bitter taste,
• Dose lower than 20mg,
• Small to moderate molecular weight,
• Good solubility in water and saliva,
• Partially non-ionized at the oral cavity’s pH,
• Ability to diffuse and partition into the epithelium of the upper GIT
(log P>1, or preferably >2),
In contrast, the following characteristics may render a drug unsuitable for delivery
as an ODT.
• Short half-life and frequent dosing;
• Very bitter or otherwise unacceptable taste because taste masking
cannot be achieved;
• Require controlled or sustained release.
1.9. Superdisintegrants:
Addition of  disintegrants  in  ODTs,  leads  to  quick  disintegration  of  tablets
and  hence improves   dissolution.  In  many  ODT  technologies  based  on  direct
compression,  the disintegrants principally  affect the rate of disintegration and
hence the dissolution. Tablet disintegration  time  can  be  optimized  by
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concentrating  the  disintegrants.  Below  critical concentration, tablet  disintegration
time is inversely proportional to disintegrants concentration. Above the critical
concentration level, however, disintegration time remains approximately constant or
even increase.33
Microcrystalline  cellulose,  cross  linked  carboxy  methyl  cellulose  sodium,  cross
linked polyvinyl   pyrrolidone  and  partially  substituted  hydroxypropyl  cellulose,
though  water insoluble, absorb water and swell due to capillary action.
Fast   disintegration    of    tablets    can    also    be    achieved    by    incorporating
effervescent disintegrating  agents, which generates carbon dioxide. This
phenomenon also resulted in partial taste masking of unacceptable taste of the drug.
The major drawback of effervescent excipients is their hygroscopicity (i.e., the
ability to absorb   atmospheric  moisture).  Hence,  their  manufacture  requires
control  of  humidity conditions  and  protection  of  the  final  product.  This  is
reflected  by  overall  cost  of  the product.54
Method of addition:
Disintegrants  are  substances  or  mixture  of  substances  added  to  the  drug
formulation that facilitates the breakup or disintegration of tablet or capsule content
into smaller particles that dissolve more rapidly than in the absence of
disintegrants. Superdisintegrants are generally used at a low level in the solid
dosage form, typically 1-15% by weight relative to the total weight  of  the  dosage
unit.  Examples  of  superdisintegrants  are  croscarmellose  sodium, crospovidone,
sodium starch glycolate which represent examples of a cross linked cellulose, cross
linked polymer and a cross linked starch respectively.
Disintegrants are essentially added to tablet granulation for causing the compressed
tablet to break or disintegrate when placed in aqueous environment.
There are three methods of incorporating disintegrating agents into the tablet:
• Internal addition (Intra granular)
• External addition (Extra granular)
• Partly internal and external
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In external addition method, the disintegrant is added to the sized granulation with
mixing prior  to  compression.  In  Internal  addition  method,  the  disintegrant  is
mixed  with  other powders before wetting the power mixtures with the granulating
fluid. Thus the disintegrant is incorporated within the granules. When these methods
are used, part of disintegrant can be added internally and part externally.
This provides immediate disruption of the tablet into previously compressed
granules while that disintegrating agent within the granules produces further
erosion of the granules to the original powder particles. The two step method
usually produces better and more complete disintegration than the usual  method of
adding the disintegrant to the granulation surface only.54
Mechanism of action:
Disintegrant is a substance or mixture of substances added to tablets to facilitate its
break up or  disintegration.  The active constituents must be released from the tablet
as efficiently as possible to allow its rapid action. The mechanism by which the
tablets are broken into small pieces and then produces a homogeneous suspension is
based on:
• Capillary action
• High swellability
• Capillary action and high swellability
• Deformation
By capillary action:
Here the medium penetrates into the tablet and replaces the air adsorbed on the
particulars, which weakens the intermolecular bond and breaks the tablet into fine
particles. Water uptake by tablet depends upon  hydrophilicity of drug/excipient and
on tabletting conditions. For these  types of disintegrants  maintenance  of porous
structure  and  low  interfacial  tension towards aqueous fluid is necessary which
helps in disintegrations by creating a hydrophilic network around the drug particles.
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By swelling action:
Although not all effective disintegrants swell in contact with water, swelling is
believed to be a   mechanism   in   which   certain   disintegrating   agents   (such   as
starch)   impart   their disintegrating effect.
By swelling in contact with water, the adhesiveness of other ingredients in a tablet
overcomes causing the tablet to fall apart.
Deformation:
Starch grains are generally thought to be “elastic” in nature meaning that are
deformed under pressure will  return to their original shape when that pressure is
removed. But, with the compression forces involved with tabletting, these grains
are believed to be deformed more permanently and are said to be “energy rich”
with this energy being released upon exposure to water.
In other words, the ability for starch to swell is higher in “energy rich” starch grains
than it is for starch grains that have not been deformed under pressure.53
It is believed that no single mechanism is responsible for the action of most
disintegrants. But rather; it is more likely the result of inter-relationships between
these major mechanisms.
Table 2: Superdisintegrants and their properties57
Superdisintegrant Nature Properties Mechanism
Crospovidone
Cross-linked homo
polymer of N-vinyl-2-
Pyrrolidone
Particle size- 100
microns.
Both swelling and
wicking.
Croscarmellose
Sodium
Cross-linked form of
Sodium CMC (Carboxy
methyl cellulose)
Insoluble in water.
Gives smoother
mouth feel.
Particle size -200
microns.
Swelling.
Sodium Starch
Glycolate
Cross-linked low
substituted carboxy
methyl ether of poly-
glucopyranose
Insoluble in water.
Particle size -140
microns.
Water uptake
followed by rapid and
enormous swelling.
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Need for the study:
Asthma  is  a  chronic  inflammatory  disease,  which  includes  bronchial
hyperactivity  and bronchospasm characterized by hyper responsiveness of trachea
bronchial  smooth  muscle  to  variety   of   stimuli,   resulting   in   narrowing   of   air
tubes,  often  accompanied  by  increased secretions and mucosal edema resulting in
breathlessness or dyspnea, wheezing cough and chest congestion.
Asthma affects over 5-10% of population in industrialized countries. It afflicts
approximately
53 million people across world mostly in United States, France, Germany, Italy,
Spain, United  Kingdom  and  Japan.50 The  treatment  of  asthmatic  symptoms
generally  includes conventional oral dosage forms  like tablets, capsules, oral
liquids etc.; inhalation therapy includes metered dose inhalers with or without
spacers, dry powder inhalers and other aerosol systems.
Oral  administration  is  the  most  widely  accepted  route  of  delivery  due  to  its
ease  of administration,  convenience, versatility and most importantly patient
compliance. Several new technologies for oral delivery have recently been
available to address the problems of physicochemical  and  pharmacokinetic
characteristic  of  drugs,  while  improving  patient compliance.
One of these include fast dissolving technology which offers the advantages of
both solids and liquids such  as quick disintegration and dissolution of tablets, no
residue in mouth, requires  no  water  intake,  provides  a  pleasant  mouth
feel.51An  attempt  was  made  for preparation of fast dissolving tablets of a model
bronchodilator, Salbutamol sulphate with an aim of reducing the lag time and
providing faster onset of action to relieve immediately acute asthmatic attack. This
would be advantageous as conventional solid oral  dosage forms are often
associated with a longer lag time and thus slower onset of action, while oral
liquids prove to have faster onset of action but require careful handling. Aerosol
systems are specific but  fail  to  deliver  the  actual  dose  of  drug  with  only  ten
percent  of  administered  dose deposited on the bronchi while rest of the drug is
deposited in oro-pharynx and is swallowed.
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Also, metered dose systems are less potable while dry powder inhalers cause
clogging of device  and   require  skillful  operation.  A  fast  dissolving  tablet
form  would  thus  be advantageous,  as  Salbutamol  sulphate  is  water-soluble
and  its  preparation  into  a  fast dissolving form would render it to dissolve rapidly
and thereby result in rapid absorption.51
The  concept  of  mouth  dissolving  drug  delivery  system  emerged  from  the  desire  to
provide patient with  more conventional means of taking their medication. It is
difficult for many patients  to  swallow  tablets  and  hard  gelatin  capsules.  Hence,
they  do  not  comply  with prescription, which results in high incidence of non-
compliance and ineffective therapy.
In some cases such as motion sickness, sudden episodes of allergic attacks or
coughing and unavailability of water, swallowing conventional tablets may be
difficult. Such problems can be  resolved  by  means  of  mouth  dissolving  tablets
when  put  on  tongue  these  tablets disintegrate and dissolve rapidly in saliva
without need of drinking water. The faster the drug disintegrates in to solution, the
quicker the absorption and onset of clinical effect. Some drugs are absorbed from the
mouth, pharynx and esophagus as the saliva passes down  into the stomach. In
such cases, bioavailability of drug is significantly greater than those observed from
conventional tablets dosage form.51
Hence,  in  the  present  study  an  attempt  will  be  made  to  formulate  mouth  dissolving
tablets of salbutamol  sulphate  (a  direct-acting  sympathomimetic  with
predominantly  ?-adrenergic activity and a selective  action  on ?2 receptor
??2agonist), used as bronchodilators in the management of reversible obstruction
as  in asthma, with a view to develop a convenient means of administration to
those patients suffering from difficulties in swallowing, nausea and motion sickness.
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Past Work On Mouth Dissolving Tablets:
? Popa G et al., 200053 optimized orodispersible tablets of Meloxicam. The
tablets were made  by  non  –aqueous  wet  granulation  using  crospovidone
and  mannitol.  A  22 factorial  design  was  used  to  investigate  the  amount
of  crospovidone  and  taste masking, smoothening hydrophilic agents
(mannitol), as independent variables and disintegration time as dependent
response.  The  results  show  that  the  presence  of  a super disintegrant and
mannitol is desirable for orodispersion.
? Prabu et al., 201054 prepared disintegrating tablets of taste masking drug.
Taste masking was done by complexing  Ondansetron HCL with amino alkyl
methacrylate copolymer in  different ratios by precipitation method. Taste
evaluation of Rapidly Disintegrating Tablet in human volunteers revealed
considerable taste masking with the degree of bitterness below threshold value
ultimately reaching to within 15mins.
? Reddy et al., 200255 prepared  rapidly  disintegrating  tablets  of
Chlorpheniramine maleate, a bitter drug. The taste masked granules were
prepared using amino alkyl methacrylate  copolymer by the extrusion method.
The taste masked granules were directly compressed into tablets using Sodium
Starch Glycolate as super-disintegrant. Tablets having good taste and
disintegrated in the oral cavity is within 30secs.
? Redkar et  al., 200256 attempted  to  mask  the  taste  and  to  formulate  an
oro- dispersible tablet of Ambroxyl Hydrochloride by complexation. Ion
exchange resin unlike  Indion-204 and Indion-234 were utilized for the
sorption of drug. Prepared tablets were evaluated and both the resins have
shown quick disintegration features (within 20secs), which is an important
characteristic of oro-dispersible tablets.
? Reeta et al., 201157 studied the formulation of fast dissolving tablets of
poorly soluble Carbamazepine by the direct compression technique with ?-
cyclodextrin complexes using super disintegrants, like Indion-414,
croscarmellose sodium, crospovidone and Sodium  Starch  Glycolate.  To
enhance  the  solubility  of  the  drug,  a  complex  of carbamazepine was
prepared with ?-cyclodextrin and this complex was compressed into tablets.
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The stability study was conducted as  per the ICH guidelines and the
formulations were found to be stable, with insignificant changes in  hardness,
drug content and disintegration time.
? S Schiermeir et al., 200258 evaluated the fast dissolving tablet of Terbutalin
sulfate by the  direct  compression  method  after  incorporation  of  super-
disintegrants  such  as Explotab, Ac-di-sol and polyplasdone XL in different
concentration. An increase in dissolution rate was observed.
? Sarasija et al., 200759 prepared and evaluated orodispersible tablets of
Ondansetron Hcl using a direct compression method with  combination of
glycein and chitosan  used as disintegrating substance.
?  Seager et al., 199060 developed Ondansetron Hydrochloride mouth dissolving
tablet which can disintegrate rapidly once placed in the oral cavity. Treated
agar powder was  used   along   with  regular  superdisintegrants  (AC-Di-Sol,
Polyplasdone  XL, Explotab) to check its disintegrating property.
? Seager et al., 199861 prepared   Ondansetron    Hydrochloride    tablet    by
direct Compression using sodium starch glycolate and croscarmellose
sodium as superdisintegrants.  The results of in vitro disintegration time and in
vivo disintegration time indicated that the tablets dispersed rapidly in mouth
within 3 to 5 secs. Addition of superdisintegrants is a useful method for
preparing orodispersible tablets by direct compression method.
? Sreenivas et al.,200662 prepared a fast dissolving tablet of Domperidone
using  Avicel pH 102 and sodium starch glycolate by direct compression
method. An effective pleasant tasting formulation was found to have a good
hardness, disintegration time and in vitro drug release of not less than 95%
within 30 mins. The drug release was found to be increased when compared
with the marketed available dispersible tablet.
? Subranmyam et al., 200763 prepared fast water dispersible tablet containing
Domperidone for oral administration. The formulation has an enhanced
structural integrity, for instance having friability lower than 1.0% and hardness
value between 3 and 6 kg/cm2 and having a pleasant taste.
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? Sunada et al., 200264 developed   rapid oral disintegration tablets by direct
compression using co-ground mixture  prepared with a vibration rod mill. The
tablets were formed by compression using  a single punch- tabletting machine
after addition of the co- ground mixture to non-ground  D-Mannitol,
Crospovidone and Magnesium Stearate. Hence, in this crospovidone acted as
a grinding assistant for D-Mannitol in the co- grinding process, enhancing the
hardness of the tablet by increasing the contact area among powder particles.
? Suryakanta et al., 201065 prepared rapidly disintegrating tablet using
microcrystalline cellulose  (Avicel  PH-M  series),  a  new  type  of
pharmaceutical  excipient  that  is spherical and has a very small particle size
instead of conventional microcrystalline cellulose used in formulation  of the
tablets. To decrease the sense of roughness, rapidly disintegrating tablets
can be prepared  by direct compression method when suitable excipients such
as fine microcrystalline cellulose  (PH-M-06) and spherical sugar granules are
used.
? T. Hanawa et al., 199566 evaluated the effects of the oral Ondansetron
disintegration tablet on the incidence of the  emesis in children undergoing
tonsillectomy with and without adenoidectomy  and  with  and  without
bilateral  myringotomy  and  tube  insertion. Randomized patients were
selected and they were followed for the first 3 days after surgery. At home
use of oral disintegrating  tablet may prevent emesis in children during the
first 3 days after tonsillectomy in children.
? Tripati et  al., 200867 formulated  and  developed  taste-  masked  rapid
disintegrating formulations of Cetirizine hydrochloride using various grades
of HPMC (Hydroxy Propyl Methyl  Cellulose) for patients, who experience
difficulty in swallowing the tablet. Taste masking could be achieved using
suitable sweeteners, flavors and sour ingredients.
? Wilkosz et al., 200368 produced a novel, a taste masked, fast disintegrating
tablet of  Famotidine.  The  disintegration  time  was  improved  considerably  by
controlling ambient   humidity   during   the  compression  process.  A   new
fast-disintegrating technology made it  possible to use low compression force,
there was no change in structure or dissolution rate of the taste- masked
particles after compression.
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? Y Morita et  al., 200269 reported  the  formulation  of  mouth  dissolving
tablets  of Roxithromycin, Dicyclomine HCl and Montelukast sodium using
Indion 414 as super disintegrant. It  was found, that Indion 414 exhibited
very good superdisintegrant action resulting in cost  effective  formulation and
that their use can be extended to various other fast disintegrating dosage forms
? Yunxia et  al., 199670 evaluated  rapidly  disintegrating  tablets  prepared
by  a  direct compression   method   using   excipients   like   microcrystalline
cellulose,   lactose croscarmellose sodium and erythritol. Within the optimal
region the minimum tensile strength was 5 kg/cm2, while the  maximum
disintegration time was 15 secs. The method described here was useful for the
preparation of rapidly disintegrating tablets.
? A. Watanabe et al., 199471 developed orodispersible tablets of Ondansetron
Hcl by Direct compression technique using various superdisintegrants,
such as SSG, croscarmellose, individually and in combination. Results have
shown that orodispersible tablets have a greater drug release than marketed
conventional tablet formulations.
? AC Liang et al.,200172 developed Metformin Hcl fast disintegrating tablets
by using polacrillin potassium NF from different sources and
superdisintegrants such as indion  294,  tulshion  349,  doshion,  ambrilite.
The  results  reveal  that  the  tablets containing disintegrants had a good
dissolution profile.
? Akihiko et al., 199673 developed Metformin Hcl orodispersible tablets
using natural disintegrants isphagula husk and synthetic disintegrants
crospovidone. Results have shown that tablets prepared with isphagula husk
have a greater dissolution rate.
? Ansel et  al.1995,74 prepared  orodispersible  tablets  of  Baclofen  using
various concentrations  of  superdisintegrants  like  Ac-di-sol,  crospovidone,
sodium  starch glycolate   by   direct   compression   method.   Results
revealed   that   disintegrant concentration affects the dissolution rate of the
drug and superdisintegrants addition technique  is a  useful  for  preparing
Orodispersible tablets by  direct compression technique.
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AIM AND OBJECTIVE OF THE STUDY
• To prepare and evaluate Oro dispersible tablets of salbutamol sulphate using
different super disintegrants in various concentrations by the process of wet
granulation
• To do in vitro drug release studies using USP type II dissolution apparatus.
• To optimize the formula having the greatest bioavailability.
• To prepare and evaluate ODTs of the optimized formulation by
changing the manufacturing methods to direct compression and
sublimation.
• To compare the drug release profile of the orodispersible tablet
with that of a marketed conventional tablet.
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PLAN OF WORK
• Selection of drug and excipients.
• Preparation of standard graph of the drug in suitable media.
• Solubility studies of salbutamol sulphate in various media.
• Preformulation studies: Drug -excipient compatibility, powder properties
• Preparation of oro dispersible tablets of salbutamol sulphate by wet
granulation method using different concentrations of superdisintegrants.
• Evaluation of the prepared tablets and optimizing the formulation having a
better release profile.
• Preparation of ODTs of the optimized formulation by changing the manufacturing
methods to direct compression and sublimation and then evaluating them to
optimize the best method.
• Comparing the best formulation with a marketed conventional tablet of salbutamol
sulphate.
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5.1. Drug profile of Salbutamol sulphate
Chemical Names:
a) 1, 3-benzene dimethanol ??{[(1,1-dimethyl ethyl) amino] methyl}-4-
hydroxysulphate (2:1) salt.
b) M-xylene-???? diol ?? [(tert butyl amino) methyl] 4-hydroxy ?? [(tertbutylamino)
methyl]-4 hydroxy m-xylene ?, ??-diol.
c) ? (tertbutylamino)-1-(4-hydroxy 3 hydroxy methyl phenyl) ethanol.
d) 4-hydroxy-3-hydroxy-methyl ? [(terbutylamino) methyl] benzyl alcohol. e) 1-(4-
hydroxy-3 hydroxy methyl phenyl)-2 (terbutylamino) ethanol
Structural Formula:
Molecular weight: 288.35
Description: White or almost white powder, odorless and slightly bitter in taste.
Standards: Salbutamol sulphate IP (1985) contains not less than 98% and not
more than 102% salbutamol calculated with reference to the dried substance.
Solubility: Soluble one in four parts of water. Slightly soluble in ethanol, 96%
chloroform and ether.
Storage: It should be protected from light.
Melting point: 150ºC.
Synonym: Albuterol sulphate.
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Category: This drug is a selectively acting beta-2-receptor stimulant (agonist)
essentially devoid of ? and ? activity. It is a direct acting adrenergic,
sympathomimetic bronchodilator.
Pharmacokinetic properties: Absorption:
Rapidly absorbed after oral administration and after inhalation; most of the inhaled
dose is swallowed and more enters the lungs with positive intermittent breathing than
by aerosol.
Distribution:
After an oral dose of 4-8mg, peak plasma concentration of about 23ng/ml for
unchanged drug and 50-100ng/ml for drug plus metabolite are attained in 2.5-3hrs.
After an inhaled dose of 80 ?g, peak plasma concentrations of about 0.2ng/ml for
unchanged drug and about 1ng/ml for drug plus metabolite are attained in about
3hrs; 2hrs after an intravenous dose of 200?g plasma concentration of about 1ng/ml
is obtained for the unchanged drug and about 2ng/ml for drug plus metabolite.
Metabolism:
The  drug  is  metabolized  by  the  first  pass  metabolism,  the  reactions  and  metabolites
involved are not yet identified.
Elimination:
About 75-95% of an oral dose is excreted in urine and about 4% in the feces in 3
days, after administration as an aerosol, up to 97% is excreted in the urine and
about 11% in the feces, after IV dose 80% is excreted in the urine and 4% in feces,
about 20% of an inhaled dose is lost in the air and in the oral adapter following oral
administration or inhalation. About 50- 60% of the urinary excreted material is
metabolized but after intravenous administration only about 27% is excreted in
metabolized form. The inactive metabolite is sulphate conjugate and about 25% of the
administered dose is metabolized to the sulphate ester.
Half-Life:
Plasma  half-life  is  2-7hrs.  In  general,  the  shorter  half-life  is  seen  with
intravenous administration, the intermediate values after oral administration and the
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longer values after aerosol  inhalation.  It  has  been  suggested  that  the  slightly
extended  half-life  following inhalation may be due to slow removal of active drug
from the lungs. Salbutamol does not cross the blood brain barrier to a significant
extent, but it crosses the placental barrier
Pharmacology:
Salbutamol exerts a relatively selective action on the ?2 adrenergic receptors of the
bronchial and vascular  smooth  muscles.  It  is  administered  either  by  inhalation
or  orally  for  the symptomatic relief of bronchospasm associated with chronic or
acute asthma, bronchitis or other obstructive pulmonary diseases.
Action:
Salbutamol is a directly acting sympathomimetic amine with a more selective
action than isoprenaline. Albuterol is long lasting and less likely to cause
cardiovascular side effects than other  adrenergic  bronchodilators.  It  may  be  a
preferred  adrenergic  agonist  because  it produces minimal arrhythmia and fall in
the partial pressure of peripheral arteriolar oxygen. It causes slight fall in blood
pressure rather than an increase.
Uses:
It is used in the treatment of asthma, chronic bronchitis, emphysema and other
broncho- pulmonary disorders involving bronchospasm. The drug is also used to
arrest premature labor and in ocular hypertension. In congestive heart disease, it is
used for low output states. The drug improves cardiac output by reducing left
ventricular after load but has little effect on ventricular filling pressure.
Dose:
Salbutamol is used as the base in aerosol inhalers and as the sulphate salt in other
dosage forms. A dose equivalent to 2 to 4mg of salbutamol, 3 or 4 times per day is
prescribed for adults, while for children of  2-6years, a dose of 1-2mg, 3 or 4
times and 2mg for older children is prescribed.
Salbutamol is administered as an aerosol inhalation in doses of up to 200µg 3 or 4
times a day. The usual  dose for children is on inhalation of 100µg 2-4 times
daily. Salbutamol sulphate is used as a respiratory solution containing the
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equivalent of 0.5% salbutamol.  A solution for injection containing the equivalent
of 50 or 500µg or one mg of salbutamol per ml is used in bronchospasm.
The usual dose by subcutaneous or intramuscular injection is equivalent of 8µg of
salbutamol per kg body  weight every 4 hours and slow intravenous injection,
4µg/Kg body weight, repeated as necessary.
Note: 1.2mg of salbutamol sulphate is approximately equivalent to 1mg of salbutamol.
Adverse effects:
Salbutamol  sulphate  may  give  rise  to  tremor  of  skeletal  muscle  (fine  finger
tremor), palpitations  and  muscle  cramps,  slight  tachycardia,  tenseness,  headaches
and  peripheral vasodilation  after  longer  doses.  The  injection  may  give  rise  to
nausea,  vomiting  and headache. This can be treated by using a cardioselective ?-
adrenoreceptor blocking agent.
Precautions and contraindications:
It is contraindicated in patients with hypertension, myocardial insufficiency and
hyperthyroidism and in patients with diabetes mellitus, serious cardiovascular
disorders. The excessive use of  spray may lead to fatal results. It should not be
administered with non- selective beta adrenoreceptor blocking drugs such as
propranolol or oxprenolol.
Tolerance:
In  healthy  subjects   specific  airway   conductance   was  progressively   decreased
when Salbutamol up to 400?g 4 times daily was inhaled over a period of 40 weeks.
Hydrocortisone 200mg IV or aminophylline will restore the response.
5.2. Excipient profile Croscarmellose sodium Synonyms:
Ac-Di-Sol, cross-linked carboxy methyl cellulose sodium, modified cellulose gum,
Nymcel, Primellose, Solutab.
Functional Category:
Tablet and Capsule disintegrant.
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Applications:
As  a  disintegrant  for  tablets  (wet  granulation  and  direct  compression),  capsules  and
granules in 2-5 % concentration.
Description:
Odorless, white colored powder.
Solubility:
Insoluble in water, although it swells to 4 to 8 times its original volume on
contact with water.
Stability:
It is a stable though hygroscopic material.
Storage conditions:
It should be stored in a well-closed container in a cool and dry place.
Incompatibilities:
Efficacy may be slightly reduced in formulations containing hygroscopic
excipients like sorbitol.
Safety:
It is generally regarded as a non-toxic and non-irritant material. However, oral
ingestion of large quantities may have a laxative effect.
Crospovidone
Synonyms:
Cross-linked povidone, Polyplasdone XL, (PVPP) poly vinyl poly pyrrolidone.
Functional Category: Tablet disintegrant.
Applications:
This is a water insoluble tablet disintegrant used at 2-5 % concentration, in tablets
prepared by direct compression or wet and dry granulation method.
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Description:
White to creamy-white, finely divided, free-flowing, practically tasteless, odorless
or nearly odorless and hygroscopic powder.
Solubility:
Practically insoluble in water and most organic solvents.
Stability:
Crospovidone is stable.
Storage conditions:
Since  it  is  hygroscopic  it  should  be  stored  in  an  airtight  container  in  a  cool  and  dry
place.
Incompatibilities:
When exposed to a high water level it may form molecular adducts with some
materials.
Safety:
It is generally regarded as a non-toxic and non-irritant material.
Sodium starch glycolate
Synonyms:
Carboxymethyl starch, Explotab, Primogel.
Functional Category:
Tablet and capsule disintegrant.
Applications:
As a disintegrant in tablet (wet granulation and direct compression) and capsule
formulations in 2-8 % concentration.
Description:
White to off-white, odorless, tasteless, free-flowing powder.
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Solubility:
Practically insoluble in water, sparingly soluble in ethanol (95 %).  In water it
swells up to 300 times to its volume.
Stability: It is a stable material.
Storage conditions:
It should be stored in a well-closed container to protect from wide variations in
humidity and temperature that may cause cracking.
Incompatibilities:
Incompatible with ascorbic acid.
Safety:
It is generally regarded as a non-toxic and non-irritant material.
Microcrystalline cellulose
Synonyms:
Avicel, cellulose gel, crystalline cellulose, E460, Emocel, Fibrocel,Tabulose, Vivacel.
Functional Category:
Tablet and capsule diluent, suspending agent, adsorbent and tablet disintegrant
Applications:
As  a  diluent  in  tablets  (wet  granulation  and  direct  compression)  and  capsule
formulations. In addition to its use as a diluent, it also has some lubricant and
disintegrant property.
Description:
White-colored, odorless, tasteless crystalline powder composed of porous particles.
Available in different particle size grades which have different properties and
applications.
Solubility:
Slightly soluble in 5 % w/v sodium hydroxide solution, practically insoluble in
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water, dilute acids and most organic solvents.
Stability:
It is a stable, though hygroscopic material.
Storage conditions:
The bulk material should be stored in a well-closed container in a cool and dry place.
Incompatibilities:
Incompatible with strong oxidizing agents.
Safety:
It is generally regarded as a non-toxic and non-irritant material.
Description:
White-colored, odorless, tasteless crystalline powder composed of porous particles.
Available in different particle size grades which have different properties and
applications.
Solubility:
Slightly soluble in 5 % w/v sodium hydroxide solution, practically insoluble in
water, dilute acids and most organic solvents.
Stability:
It is a stable, though hygroscopic material.
Storage conditions:
The bulk material should be stored in a well-closed container in a cool and dry place.
Incompatibilities:
Incompatible with strong oxidizing agents.
Safety:
It is generally regarded as a non-toxic and non-irritant material.
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Table 3: List of materials used and manufacturer
S.NO. MATERIALS MANUFACTURER
1
2
3
4
5
6
Drug (Salbutamol sulphate)
Diluent (Avicel)
Superdisintegrants (Polyplasdone, Explotab, ac-di-sol)
Glidant (Aerosil)
Lubricant(Magnesium fumarate)
Flavor (mango )
Cipla ,India
SK Pharm ltd.,hyd SK
Pharm ltd.,hyd SK
Pharm ltd.,hyd SK
Pharm ltd.,hyd krishna
Pharm.,hyd
Table 4: List of equipments used
S.NO EQUIPMENT MANUFACTURER
1
2
3
4
5
6
UV-Vis spectrophotometer
Rotary tablet punching machine
Dissolution apparatus
Friabilator
Hardness tester
Electronic balance
Elico corporation instruments (SL 162)
Rimek, Ahmedabad.
Electro lab TDT- 08L, Mumbai.
SECOA, New Delhi.
Monsanto hardness tester, Hyd.
AW 120, Shimadzu Corporation, Japan.
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6.1. Evaluation of pre-compression blend
1. Angle of repose:
The prepared granules were assessed for the flow property by determining the
angle of repose. The angle of repose was measured by allowing the granules to fall
over a graph sheet placed on horizontal surface  through  a funnel kept at a certain
convenient height (about 6 cm). The height of the heap (h) was measured and then
circumference of the base of heap (r) was drawn on graph sheet with the help of a
pencil. The radius of the circle obtained was measured. The angle of repose was
calculated by the following equation.
tan ? = h/r or ?  = tan-1 (h/r)
Where ?   = angle of repose
h = height of the heap
r = radius of the base of the heap.
Table 5: Angle of repose as an indication of powder flow properties
FLOW PROPERTIES ANGLE OF REPOSE (O)
Excellent 25-30
Good 31-35
Fair 36-40
Passable 41-45
Poor 46-55
Very poor 56-65
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2. Bulk density:
It is the ratio of total mass of granules to the bulk volume of granules. It was
measured by pouring the weighed granules into a measuring cylinder and initial
volume was noted. This initial volume is called the bulk volume. From this the bulk
density is calculated according to the formula mentioned.
It is expressed in gm/ml and is given by,
?b = M V
VB
Where,  M =    mass of granules
  Vb  =    bulk volume
3. Tapped density:
After determining the poured bulk density, the measuring cylinder containing known
mass of powder was  tapped mechanically for fixed time to attain constant
volume, called tapped density.
Tapped density = Mass of granules
Tapped volume of granules
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4. Carr’s index (percentage compressibility):
Using bulk density and tapped density the percentage compressibility of powder
blend was determined, which is given as Carr’s compressibility index.
Carr’s compressibility index (%)  =  Tapped density- Bulk density ×100
              Tapped density
Table 6: Percentage compressibility and flowability of powder
PERCENTAGE COMPRESSIBILITY FLOWABILITY
5 – 12 Excellent
12 – 16 Good
18 – 21 Fair Passable
23 – 35 Poor
33 – 38 Very Poor
< 40 Very Very Poor
5. Hausner’s ratio:
It is determined by the ratio of tapped density and bulk density. Hausner’s ratio is an
indirect index of ease of powder flow. It is calculated by the following formula.
Hausner’s Ratio = Vt /Vb
Where,
Vt = tapped density
Vb = bulk density
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Table 7: Table showing flow character and Hausner’s ratio
FLOW CHARACTER HAUSNER’S RATIO
Excellent 1.00 – 1.11
Good 1.12 – 1.18
Fair 1.19 – 1.25
Passable 1.26 – 1.34
Poor 1.35 – 1.45
Very Poor 1.46 – 1.59
6.2. Drug excipient compatibility
Physical observation (stability):
The drug was mixed with different proportions of the excipients which were used
in the formulation, in different ratios and kept at varying temperatures for a period
of one month. The physical properties (color change) were monitored regularly. The
change in color of any mixture was considered as incompatibility.
FT-IR studies:
The drug, physical mixture and the powdered tablet were subjected to IR studies to
observe for any incompatibility between the drug and excipients.
6.3. Solubility studies of Salbutamol sulphate:
10 mg of the drug was dissolved in 100 ml of each of the solvent (water,
phosphate buffer and ethanol) separately and mixed well. Absorbance of the
resultant solution (5ml sample) was measured using U.V Visible spectrophotometer
against distilled water as blank at a wave length of 275nm. Concentrations were
calculated with the help of standard graph and total amount of drug solubilized in
1ml of the solvent was obtained.
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Table 8: Solubility terms
Solubility term Parts of solvent required for 1 part of solute
Very soluble
Freely soluble
Soluble
Sparingly soluble
Slightly soluble
Very slightly soluble
Practically insoluble
Less than 1 part
1-10 parts
10-30 parts
30-100 parts
100-1000 parts
1000-10,000 parts
>10,000 parts
6.4. Standard graph of Salbutamol sulphate in phosphate buffer of pH 6.8:
A  standard  graph  of  pure  drug  in  suitable  medium  was  prepared  by
plotting  the concentrations on X-axis and absorbance / optical density on Y-axis.
Procedure:
Accurately weighed  amount  of 100  mg  of Salbutamol  sulphate  was  taken  in  a
100  ml volumetric flask. The volume was made up to 100 ml with 6.8 pH
phosphate buffer, which constitutes the stock solution of 1 mg/ml. By further
diluting the stock solution suitably with fresh buffer, solutions of 1, 3, 5, 7, 10 and
15?g/ml concentrations were prepared. These solutions were checked for their
absorbance using UV-Vis Spectrophotometer at ?max275 nm against distilled water as
blank and a standard graph was plotted.
6.5. Manufacturing methods used:
a)  Wet granulation
b)  Direct compression c)   Sublimation
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a) Wet granulation:
The steps  followed  in  the  formulation  of  ODTs  by  wet  granulation  technique
includes weighing, mixing, moistening, wet screening, drying, dry screening, addition
of lubricant and glidant and compressing.
Procedure:
All the required ingredients were weighed.  Whole amount of drug, diluent, half of
the  amount  of  disintegrant  were  taken  and  wet  mass  was  prepared  with  water.  This
wet mass is passed through sieve no. 10 to form the granules.
The granules were dried, these are again screened. To this mixture the remaining
disintegrant, lubricant, and  glidant and flavor were added. The final mixture was
shaken manually for
10mins in a plastic bag. Final blend was compressed into tablets using 7mm
round, flat punches at corresponding dies on rotary compression machine.
b) Direct compression:
All the required ingredients were passed through sieve no.10 to get uniform sized
particles and were weighed accurately. Whole amount of drug, superdisintegrant,
diluents and flavor were mixed in the increasing order of their weights in a
polythene bag. To this mixture the glidant and lubricant were added .The final
mixture was shaken manually for 10 mins in a plastic bag. Final blend was
compressed into  tablets using 7mm round, flat punches at corresponding dies on a
rotary compression machine.
The process is similar for all the formulations, which were prepared by
direct compression technique.
Sublimation:
Here, an additional ingredient - subliming agent (e.g. camphor) was added to the
mixture and directly compressed. The resulting tablets were dried to volatilize any
residues of camphor.
6.6. Evaluation of the prepared tablets
Different quality control tests were performed for all the ODT formulations to check
whether these have met  the specifications given in USP along with other in vitro
tests like wetting time and water absorption ratio.
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Various in vitro tests performed are:
?  Weight variation
?  Hardness and Friability
?  Assay
?  Wetting time and Water absorption ratio
?  Disintegration Time
?  Dissolution
Weight variation test:
20 tablets were randomly selected from each formulation and their average
weight was calculated using digital balance. Individual weight of each tablet was
also calculated using the same and compared with the average weight.
Table 9: Limits for uniformity of weight
Average weight of  tablets
(mg)
Maximum percentage difference
allowed
130 or less 10
130-324 7.5
More than 324 5
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Hardness:
The tablet hardness of different formulations was measured using the Monsanto
hardness tester. The tester  consists of a barrel containing a compressible spring
held between two
plungers. The lower plunger was placed in contact with the tablet and a zero was
taken.		
The upper plunger was then forced against the spring by turning a threaded bolt
until the tablet fractures. As the spring is compressed, a pointer rides along a
gauge in the barrel to indicate the force. The force of fracture is recorded and the
zero force reading is deducted from it. Generally, a minimum hardness of 4 kg is
considered acceptable for uncoated tablets. The hardness for ODTs should be
preferably 1-3 kg.
Friability (F):
This test is performed using a laboratory friability tester known as Roche
Friabilator. 10 tablets were weighed and placed in a plastic chambered friabilator
attached to a motor, which revolves at a speed of 25  rpm,  dropping the tablets from
a distance of 6 inches with each revolution.
The tablets were subjected to 100 revolutions for 4 mins. After the process, these
tablets were de- dusted and reweighed. Percentage loss of tablet weight was calculated
using the formula-
Where w0 = initial weight
W=final weight
Assay of the Tablets:
The  formulated  orally  disintegrating  tablets  were  assayed  for  the  drug  content.
In  each formulation, samples containing amount of powder equivalent to one dose of
drug were taken in triplicate and assayed for content of drug
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Method:
10 tablets were randomly selected, weighed and finely powdered; powder equivalent
to one tablet was added to 100ml of distilled water in a conical flask. The conical
flask was placed on a rotary shaker overnight. An  aliquot of solution was
centrifuged and supernatant was filtered through a 0.22µ filter. Absorbance of the
resulted supernatant solution was measured using U.V Visible spectrophotometer
against distilled water as  blank at a wave length of
275nm.
Concentrations were calculated with the help of standard graph and total amount
present in the formulation was calculated.
Wetting time and Water absorption ratio (R):
Five circular tissue papers were placed in a petridish with a 10-cm diameter. Ten
milliliters of water containing methylene blue, a water-soluble dye, was added to
the petridish. The dye solution is used to identify the complete wetting of the tablet
surface.  A tablet  was  carefully  placed  on  the  surface  of  tissue  paper  in  the  petridish
at room temperature. The time required for water to reach the upper surface of the
tablets and completely wet them was noted as the wetting time. To check for
reproducibility, the measurements were carried out in replicates (n=6). The wetting
time was recorded using a stopwatch.
The weight of the tablet before keeping in the petridish was noted (Wb ) using digital
balance. The wetted  tablet  from the petridish was taken and reweighed (Wa ) using
the same. The water absorption ratio, R, was determined according to the following
equation:
R = 100 (Wa - Wb ) / Wb
Where Wb and Wa are the weight before and after water absorption respectively.
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Disintegration Time:
Disintegration time is considered to be one of the important criteria in selecting
the best formulation. To achieve correlation between disintegration time in vitro and
in vivo (in oral cavity) several methods were proposed, developed and followed at
their convenience. One of the simple methods followed is described below.
Disintegration time was measured using a modified disintegration method (n=6).
For this purpose, a petridish (10cm diameter) was filled with 10ml of water. The
tablet was carefully put in the center of the petridish and the time for the tablet to
completely disintegrate into fine
particles was noted using a stop watch.
Dissolution test:
Drug release from ODTs was studied by using dissolution rate test apparatus.
ODTs of desired formulation were taken and placed in the vessels of dissolution
apparatus.
5ml aliquots were collected from the vessels at different time intervals, replenished
with  same  volume  of  the  blank  solution  and  analyzed  by  using  UV  Visible
spectrophotometer at 275nm. Drug concentration was calculated from the standard
graph and expressed as percentage of drug dissolved or released. The release
studies were performed in 3 replicates and mean values were taken.
Conditions for Salbutamol sulphate:
 Apparatus : Dissolution test apparatus (USP II)
 Medium : 500 ml, phosphate buffer of pH 6.8
RPM : 50
Temperature : 37 ± 0.5 0 C Sampling
Volume : 5ml
Sampling intervals : 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30mins.
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Table 10: Standard graph of Salbutamol sulphate in pH 6.8 phosphate
buffer
Concentration (µg/ml) Absorbance
1
3
5
7
10
15
0.078
0.19
0.355
0.49
0.69
0.87
Fig 1: Standard graph of Salbutamol sulphate in pH 6.8 phosphate buffer
(at 275nm)
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Table 11: Solubility studies of Salbutamol sulphate
Solvent Solubility
Water
6.8 pH phosphate buffer
Ethanol
0.95 mg/ml (freely soluble)
0.94 mg/ml (freely soluble)
0.014 mg/ml (slightly soluble)
Salbutamol sulphate was found to be freely soluble (1-10 parts of solvent required for
1 part of solute) in water and phosphate buffer of pH 6.8, slightly soluble (100-1000
parts of solvent required for 1 part of solute) in ethanol.
Drug excipient compatibility studies:
Fig. 2: FT-IR spectrum of pure drug
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Fig. 3 : FT-IR spectrum of the physical mixture (before compression)
Fig.4 :FT-IR spectrum of the powdered tablet (F6)
Discussion:
The drug, physical  mixture and the final  formulation were subjected to IR studies to
observe for any incompatibility between  the  drug  and  excipients.  As  the  peaks
remained  unaffected,  it  can  be concluded that there is no incompatibility between
the drug and excipients.
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Table 12: Formulations (in mg)
S.NO Formulation code -
INGREDIENTS
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
1
2
3
4
5
6
7
8
9
Salbutamol sulphate
Microcrystalline cellulose
Sodium starch glycolate
Crospovidone
Croscarmellose sodium
Magnesium fumarate
Aerosil
Mango flavor
Camphor
5
92
3
-
-
0.1
0.1
0.1
5
89
6
-
-
0.1
0.1
0.1
5
86
9
-
-
0.1
0.1
0.1
5
92
-
3
-
0.1
0.1
0.1
5
89
-
6
-
0.1
0.1
0.1
5
86
-
9
-
0.1
0.1
0.1
5
92
-
-
3
0.1
0.1
0.1
5
89
-
-
6
0.1
0.1
0.1
5
86
-
-
9
0.1
0.1
0.1
5
86
-
9
-
0.1
0.1
0.1
3
Total weight: 100.3 mg
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Table 13:Evaluation of pre-compression blends:
Formulation
Code
Angle of
Repose(º)
Bulk Density
(g/cc)
Tapped Density
(g/cc)
Carr’s Index Hausner’s
Ratio
F1
F2
F3
F4
F5
F6
F7
F8
F9
24.3
23.8
23.4
26.2
24.6
22.9
27.4
26.2
24.6
2.4
2.3
2.4
2.6
2.6
2.7
2.4
2.1
2.7
1.9
1.9
1.8
2.1
2.2
2.1
1.9
1.8
2.3
14.3
17.2
19.3
15.4
14.7
15.5
17.9
14.3
15.8
0.81
0.84
0.82
0.85
0.89
0.87
0.85
0.81
0.86
The prepared granules have excellent flow properties based on the angle of repose
values (24-30). Based  on the Carr’s index and Hausner’s ratio, the compressibility
index and the flowability of the granules is excellent.
Table 14: Evaluation of tablets
Formulation
Code
Weight
variation
(mg)
Hardness
(kg/cm2)
Disinte
gration
time
(secs)
Friability
(%)
F1
F2
F3
F4
F5
F6
F7
F8
F9
98±1.3
99±0.54
104±1.9
97±1.4
98±0.98
102±1.5
103±0.8
97±0.65
99±1.9
2.4±0.33
2.3±0.24
3.2±0.46
3.0±0.12
2.7±0.15
3.1±0.17
3.0±0.32
2.8±0.33
2.0±0.19
14
14
12
09
08
06
12
10
09
0.81
0.69
0.75
0.73
0.76
0.86
0.89
0.91
0.86
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Discussion:
Weight variation was found to be within the limits as per USP-NF 24. Average
weight of 20 tablets of all nine formulations was found in the range of 98 to 104mg.
Hardness and friability of all the tablet formulations were observed in the range of
2- 3.2kg/cm2 and  0.69 to 0.91 respectively. For all the formulations, with increase
in the superdisintegrant concentration from 3-9%, the disintegration time decreased
accordingly. The tablets containing polyplasdone exhibit quick disintegration time
followed by tablets containing Ac-di-sol and explotab.
Table 15: Evaluation of tablets
Formulation
Code
Dispersion  time
(secs)
Wetting   time
(secs)
Water absorption
ratio (%)
Drug Content
(%)
F1
F2
F3
F4
F5
F6
F7
F8
F9
21
19
19
14
10
9
19
17
14
12
10
10
9
6
5
10
9
9
58
60
64
81
84
84
63
68
72
98.44
99.05
98.63
98.09
98.96
99.06
98.33
98.86
98.45
Discussion:
Water absorption ratio (R) value increased with increase in the superdisintegrant
concentration (from 3-9 %). Wetting time and water absorption ratio was found in
the range of 5-12 secs and 58-84 %, respectively.  Drug  content  of  all  the
formulations   was   found   in   the   range   of   98.33   to   99.06%.  Dispersion  time
decreased with the increase in the superdisintegrant concentration.
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Table 16: Dissolution profiles of ODTs prepared by wet granulation (measured
at 275 nm)
Time
(Min)
F1 F2 F3 F4 F5 F6 F7 F8 F9
0
3
6
9
12
15
18
21
24
27
30
0
28.91±0.12
34.65±0.45
46.45±0.09
50.36±0.08
63.88±0.05
75.51±0.33
81.36±0.17
85.25±0.19
98.42±0.23
98.66±0.44
0
42.24±0.54
46.86±0.87
54.67±0.45
69.70±0.76
81.82±0.05
85.95±0.55
98.45±0.54
98.72±0.06
0
53.44±0.46
75.43±0.54
79.45±0.23
85.24±0.09
89.12±0.89
98.44±0.41
98.46±0.57
0
32.76±0.14
36.80±0.73
50.31±0.91
60.02±0.05
69.71±0.37
77.44±0.04
79.44±0.96
85.24±0.84
99.26±0.72
99.33±0.71
0
53.96±0.61
61.97±0.05
71.65±0.17
77.48±0.53
85.22±0.63
87.45±0.19
99.24±0.91
99.32±0.87
0
67.45±0.09
81.32±0.75
87.17±0.06
89.13±0.96
99.45±0.75
99.48±0.64
0
34.69±0.35
44.52±0.04
50.24±0.25
54.24±0.24
63.90±0.17
69.73±0.13
81.33±0.12
87.17±0.54
98.33±0.33
98.54±0.04
0
46.25±0.91
54.22±0.98
61.97±0.15
71.85±0.14
79.41±0.59
85.24±0.76
98.13±0.94
98.24±0.06
0
63.45±0.03
78.32±0.05
85.25±0.09
87.91±0.14
94.86±0.17
98.69±0.12
98.97±0.06
n =3
Discussion:
In vitro dissolution studies of various formulations at different time intervals are
shown in fig. 5. The crospovidone formulation (9%) showed the maximum
dissolution rate of 99.48% drug release in 18 mins. Ac-Di-Sol (9%) containing
tablets released more than 98.66 of the drug in 18 mins and explotab (9%)
formulations   released   more   than   98.44%   of   the   drug   in   18   mins.   This
shows  that  the effectiveness of superdisintegrants was in the order of crospovidone
> Ac-Di-Sol > explotab.
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Fig. 5: Dissolution profile of ODTs of Salbutamol sulphate (formulations F1-
F9) in pH 6.8
phosphate buffer
Discussion:
As the concentration of superdisintegrant increased, the dissolution profile of the
tablet improved. This was  the  same  with  all  three  superdisintegrants.  The
release  profiles  with  crospovidone  as  the superdisintegrant were much better than
that of croscarmellose sodium and sodium starch glycolate. The formulation F6 was
found to be the most effective with the best release profile. It contained the
superdisintegrant crospovidone in the percentage of 9%.
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The same formulation was taken and the tablet was now prepared by changing the
method to direct compression and sublimation. The prepared tablets were evaluated
for their release profiles and then compared to that of a conventional tablet of
Salbutamol sulphate.
Table 17: Dissolution profiles of F6 prepared by direct compression and
sublimation compared
to that of a marketed conventional tablet
Time (min) F6
Direct
compression
Sublimation
Conventional
tablet
0
3
6
9
12
15
18
00.00
67.45±0.15
81.32±0.17
87.17±0.33
89.13±0.44
99.45±0.32
99.48±0.31
00.00
69.06±0.17
86.84±0.15
89.98±0.18
91.95±0.19
99.48±0.14
99.49±0.33
00.00
73.64±0.04
89.69±0.06
93.45±0.12
98.96±0.32
99.51±0.15
99.50±0.19
00.00
10.86
11.56
12.78
14.72
15.91
19.14
The in  vitro drug  release  profile  F6  was  compared  with  that  of  the
conventional  tablet;  the conventional  tablet  released only 19% of the drug in
18mins whereas the F6 formulation (ODT prepared by wet granulation) released up
to 99.48%. When the manufacturing method was changed to direct compression and
sublimation, there was only a slight variation in the drug release profiles, with
sublimation having a better release profile of the three methods.
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Fig.6: Comparative dissolution profiles of F6 prepared by direct compression
and sublimation to that of a conventional tablet of Salbutamol sulphate
Discussion:
Disintegration time was given the major importance in selection of the best ODT
formulation among all the formulations. For all the formulations, with increase in the
superdisintegrant concentration from 3-9%, the disintegration time decreased
accordingly. Wicking and capillary action are postulated to be the major factors in the
ability of the superdisintegrants to function.
But the tablets prepared with explotab as a superdisintegrant took more time to
disintegrate than other superdisintegrants. The tablets containing polyplasdone
exhibited quick disintegration time followed by tablets containing Ac-di-sol and
explotab. The probable reason for the delayed disintegration and wetting of the
tablets might be slow water uptake or  more gelling tendency of the Ac-di-sol and
explotab.
Bulk  densities  of  various  formulations  varied  from  2.1-2.7g/cc.  The angle  of
repose  and  the compressibility index values varied from 23° to 27° and 14 to 19
respectively. From these values, it was evident that these blends had excellent flow
properties.
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Weight variation was found to be within the limits as per USP-NF 24. Average
weight of 20 tablets of all nine formulations was found in the range of 98 to 104mg.
Hardness and friability of all the tablet formulations were observed in the range of
2- 3.2 kg/cm2 and  0.69 to 0.91% , respectively. Wetting time and water absorption
ratio was found in the range of 5-12 secs and 58-84 %, respectively. Water
absorption ratio (R) value increased with increase in the superdisintegrant
concentration (from 3-9 %).
The in vitro disintegration time was rapid with crospovidone containing batches (6-9
secs) and delayed with explotab containing batches (12-14 secs). The rapid
disintegration may be due to the rapid uptake of water from the medium,  swelling
and bursting effect.
In vitro dissolution studies of various formulations at different time intervals are
reported. The crospovidone formulation (9%) showed the maximum  dissolution rate
of 99.48% drug release in 18 mins.   Ac-Di-Sol (9%) containing tablets released
more than 98.66 of the drug in 18 mins and explotab (9%) formulations released
more than 98.44% of the drug in 18 min. This shows that the effectiveness of
superdisintegrants was in the order of crospovidone> Ac-Di-Sol >explotab.
From the overall observations, formulation F6 containing 9% w/w  crospovidone was
considered to be the best formulation in the formulations F1-F9 prepared by the
method of wet granulation. When the manufacturing method was  changed to direct
compression and sublimation, there was only a slight variation in the drug release
profiles, with  sublimation having a better release profile of the three methods.
When compared with a conventional tablet, the conventional tablet released only
19% of the drug in 18mins whereas the F6 formulation prepared by wet
granulation released up to 99.48% of the drug within the same time. The fast
dissolving tablet of salbutamol sulphate with crospovidone (9%) as the
superdisintegrant was found to be an alternative to and better than the conventional
tablet dosage form and the rapid dissolving concept in case of salbutamol  sulphate
could be of great importance in relieving acute asthmatic attacks.
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SUMMARY
Water   absorption   ratio   (R)   value   increased   with   increase   in   the   super
disintegrant concentration (from 3-9 %). Disintegration time was given the major
importance in selection of the best ODT formulation among all the formulations.
For all the formulations, with increase in the super disintegrant concentration from
3-9%, the disintegration time decreased accordingly. Wicking and capillary action
are postulated to be the major factors in the ability of the super disintegrants to
function.
But the tablets prepared with explotab as a super disintegrant took more time to
disintegrate than other  super disintegrants. The  tablets containing polyplasdone
exhibit quick disintegration time followed by tablets containing Ac-di-sol and
explotab.  The probable reason for delayed disintegration and wetting of the tablets
might be slow water uptake or more gelling tendency of the Ac-di-sol and explotab.
When  the  flowing  properties  of  the  granules  were  evaluated,  bulk  densities  of
various formulations  varied from 2.1-2.7g/cc. The angle of repose and the
compressibility index values varied from 23° to 27° and 14 to 19 respectively.
From these values, it was evident that these blends had excellent flow properties.
Weight variation was found to be within the limits as per USP-NF 24. Average
weight of 20 tablets of all  nine  formulations was found  in the range of 98 to
104mg. Hardness and friability of all the tablet formulations were observed in the
range of  2- 3.2 kg/cm2 and 0.69 to 0.91% , respectively. Wetting time and water
absorption ratio was found in the range of 5- 12 secs and 58-84 %, respectively.
Drug content of all the formulations was found in the range of 98.33 to 99.06%. The
in vitro disintegration  time was rapid with crospovidone containing batches (6-9
secs) and delayed with explotab containing  batches  (12-14 secs). The rapid
disintegration may be due to the rapid uptake of water from the medium, swelling
and bursting effect.
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In vitro dissolution studies of various formulations at different time intervals are
reported. Dissolution profiles were found be better and faster with the increase in the
concentration of the superdisintegrant. The crospovidone formulation (9%) showed
the maximum dissolution rate of 99.48% drug release in 18 mins.   Ac-Di-Sol (9%)
containing tablets released more than 98.66 of the drug in 18 mins and Explotab
(9%)  formulations released more than 98.44% of the drug in 18 min. This shows
that the effectiveness of superdisintegrants was in the order of crospovidone> Ac-Di-
Sol >explotab.
From the  overall  observations,  formulation  F6  containing  9%  w/w crospovid
one  was considered to be the best formulation in the formulations F1-F9 prepared
by the method of wet granulation.  When the manufacturing method was changed
to direct compression and sublimation, there was only a slight variation in the drug
release  profiles,  with  sublimation  having  a  better  release  profile  of  the  three
methods. The in vitro drug release profile of F6 was compared to that of the
conventional tablet; the conventional tablet released only 19% of the drug in 18mins
whereas the F6 formulation released up to 99.48%.
Thus it  can  be  summarised  that  the  fast  dissolving  tablet  of  salbutamol
sulphate  with crospovidone   (9%)  as  the  superdisintegrant  is  an  alternative  to
and  better  than  the conventional tablet dosage form.
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CONCLUSIONS
The present  study  was  undertaken  to  formulate  and  evaluate  fast  dissolving
tablets  of salbutamol sulphate by wet granulation method and comparing with the
conventional tablet. The in vitro drug release profile F6 was compared with that of
the conventional tablet, the conventional tablet released only 19% of  the drug in
18mins whereas the F6 formulation released up to 99.48%. Changing the method of
manufacture to direct compression from wet granulation resulted in only a slight
variation in the amount of drug release. However, tablets prepared by sublimation
showed a better release profile.
Thus  it  can  be  concluded  that  the  fast  dissolving  tablet  of  salbutamol
sulphate  with Crospovidone   (9%)  as  the  superdisintegrant  is  an  alternative  to
and  better  than  the conventional tablet dosage forms,  and the rapid dissolving
concept in case of salbutamol sulphate could be of a great importance in relieving
acute asthmatic attack.
Future  possibilities  for  improvements  in  FDTs  and  drug  delivery  are  bright,
but  the technology is still relatively new. Thus, it can be concluded that fast
dissolving tablets can be prepared with a view of  obtaining faster action of the drug
and would be advantageous in comparison to the currently available conventional
forms. The technique adopted was found to be economical and industrially feasible.
Salbutamol sulphate being a water-soluble drug would be readily available in a
dissolved form for rapid oral uptake. The rapid dissolving concept in case of
Salbutamol sulphate could be of great importance in relieving acute asthmatic shocks.
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